Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CCND3 | P30281 | 2/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5949639 | 0.89 | HRH2 (0.46) | KDM1ABRD4ATAD2HRH3EHMT2 | |
| SCHEMBL18551217 | 0.89 | HRH2 (0.46) | KDM1ABRD4ATAD2HRH3EHMT2 | |
| Hydrochloric Acid SCHEMBL6496133 | 0.87 | HRH2 (0.45) | KDM1ABRD4ATAD2HRH3EHMT2 | |
| SCHEMBL4547144 | 0.85 | KDM1A (0.50) | KDM1ABRD4ATAD2CARM1PRMT6 | |
| Trifluoroacetic Acid SCHEMBL21816636 | 0.84 | KDM1A (0.42) | KDM1AHRH3CARM1PRMT6HTR4 | |
| SCHEMBL4547142 | 0.82 | KDM1A (0.48) | KDM1ABRD4ATAD2EHMT2HTR4 | |
| SCHEMBL18562929 | 0.82 | HRH3 (0.38) | KDM1AHRH3CARM1PRMT6PRMT1 | |
| SCHEMBL18551063 | 0.82 | KDM1A (0.48) | KDM1ABRD4ATAD2CARM1PRMT6 | |
| SCHEMBL18873644 | 0.81 | KDM1A (0.47) | KDM1ABRD4ATAD2CARM1PRMT6 | |
| SCHEMBL18550511 | 0.81 | CYP2D6 (0.42) | KDM1AHRH3CARM1PRMT6PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050016-A9 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240365736-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4395549-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | Oerth Bio LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024050016-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023034411-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | OERTH BIO LLC (US) | 2023-03-09 | — | — | WO | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-08-13 | — | — | US | disclosed |
| US-9040522-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| WO-2014160810-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-02 | — | — | WO | disclosed |
| US-20140296200-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2011131741-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-7872003-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-18 | — | — | US | disclosed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1812446-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | SIRT1, SIRT3, SIRT5 | KDM1A 208/4885BRD4 49/4885ATAD2 1591/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | KDM1A 1044/4885BRD4 1995/4885ATAD2 1207/4885 |
| US-20240365736-A1 | COMPOSITIONS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS IN A PLANT CELL | CRBN, LTN1, CBL | KDM1A 940/4885BRD4 987/4885ATAD2 1414/4885 |
| US-20140171407-A1 | 1,7-DIAZACARBAZOLES AND METHODS OF USE | CHEK1, CHEK2, BUB1B | KDM1A 458/4885BRD4 541/4885ATAD2 2275/4885 |
| US-20140296200-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | KDM1A 79/4885BRD4 369/4885ATAD2 2330/4885 |
| US-20080207609-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | KDM1A 4053/4885BRD4 2489/4885ATAD2 4389/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | KDM1A 1400/4885BRD4 1439/4885ATAD2 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.